Efficacy of reteplase in poorly functioning hemodialysis catheters

Clinical Nephrology

Volumn 61, Issue 1, 2004, Pages 47-53

  Falk, Abigail ^a,b   Samson, W ^a   Uribarri, J ^a   Vassalotti, J A ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

End stage renal disease; Hemodialysis; Lysis; Patency; Reteplase

Indexed keywords

ALTEPLASE; RETEPLASE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPIRATION; BLOOD FLOW; BLOOD FLOW VELOCITY; BLOOD VESSEL CATHETERIZATION; CATHETER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE REMOVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE FACILITY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; PATIENT REFERRAL; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBECTOMY; THROMBOSIS; TIME; TREATMENT FAILURE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 0347135833     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP61047     Document Type: Article

References (27)

1. Adler S, Szczech L, Qureshi A, Bollu R, Thomas-John R 2001 IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 56: 428-434
2. Castner D 2001 The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters. Nephrol Nurs J 28: 403-410
3. Cobb DK, High KP, Sawyer RG, Sable CA, Adams RB, Lindley DA, Pruett TL, Schwenzer KJ, Farr BM 1992 A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters. N Engl J Med 327: 1062-1068
4. Daeihagh P, Jordan J, Chen J, Rocca M 2000 Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 36: 75-79
5. Fabrizi F, Sangiorgio R, Pontoriero G, Corti M, Tentori F, Troina E, Locatelli F 1999 Antiphospholipid (aPL) antibodies in end-stage renal disease. J Nephrol 12: 89-94
6. Falk A, Guller J, Nowakowski FS, Mitty H, Teodorescu V, Uribarri J, Vassalotti J 2001 Reteplase in the treatment of thrombosed hemodialysis grafts. J Vasc Interv Radiol 12: 1257-1262
7. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA 1993 Hemodialysis vascular access morbidity in the United States. Kidney Int 43: 1091-1906
8. Field SL, Brighton TA, McNeil HP, Chesterman CN 1999 Recent insights into antiphospholipid antibody-mediated thrombosis. Baillieres Best Pract Res Clin Haematol 12: 407-422
9. Garcia-Martin F, De Arriba G, Carrascosa T, Moldenhauer F, Martin-Escobar E, Val J, Saiz F 1991 Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant 6: 543-547
10. Haviv YS 2000 Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: cause or effect? Nephron 86: 447-454
11. Little MA, Walshe JJ 2002 A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction. Am J Kidney Dis 39: 86-91
12. Lund GB, Trerotola SO, Scheel PF Jr, Savader SJ, Mitchell SE, Venbrux AC, Osterman FA Jr 1996 Outcome of tunneled hemodialysis catheters placed by radiologists. Radiology 198: 467-472
13. Merport M, Murphy TP, Egglin TK, Dubel GJ 2000 Fibrin sheath stripping versus catheter exchange for the treatment of failed tunneled hemodialysis catheters: randomized clinical trial. J Vasc Interv Radiol 11: 1115-1120
14. Mokrzycki MC, Singhal A 2002 Cost-effectiveness of three strategies of managing tunneled, cuffed hemodialysis catheters in clinically mild or asymptomatic bacteremias. Nephrol Dial Transplant 17: 2196-2203
15. Moss AH, McLaughlin MM, Lempert KD, Holley J 1988 Use of a silicone catheter with a Dacron cuff for dialysis short-term vascular access. Am J Kidney Dis 12: 492-498
16. Moss AH, Vasilakis C, Holley JL, Foulks CJ, Pillai K, McDowell DE 1990 Use of a silicone dual-lumen catheter with a Dacron cuff as a long-term vascular access for hemodialysis patients. Am J Kidney Dis 16: 211-215
17. Northsea C 1994 Using urokinase to restore patency in double lumen catheters. ANNA J 21: 261-273
18. Obialo CI, Conner AC, Lebon LF 2000 Tunneled hemodialysis catheter survival: comparison of radiologic and surgical implantation. ASAIO J 46: 771-774
19. Prakash R, Miller CC 3rd, Saki WN 1995 Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 26: 347-352
20. Radonick V, Clark A, Boe JA 2002 A comparison of Cath Flo and Retavase in the declotting and subsequent dialysis of central venous dialysis catheters (abstract 18). Presented at 11th Annual Clinical Nephrology Meeting. Chicago, IL, USA, pp 17-21
21. Retavase 2000 Prescribing information. Malvern, PA, USA, Centocor Inc
22. Saad TF 1999 Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 34: 1114-1124
23. Smalling RW 1997 Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. Eur Heart J 18 (Suppl F): F11-16
24. Swartz RD, Messana JM, Boyer CJ, Lunde AM, Weitzel WF, Hartman TL 1994 Successful use of cuffed central venous hemodialysis catheters inserted percutaneously. J Am Soc Nephrol 4: 1719-1725
25. Trerotola SO, Johnson MS, Harris VJ, Shah H, Ambrosius WT, McKusky MA, Kraus MA 1997 Outcome of tunneled hemodialysis catheters placed via the right internal jugular vein by interventional radiologists. Radiology 203: 489-495
26. US Renal Data System 1999 USRDS 1997 Annual Report IV: The USRDS dialysis morbidity and mortality study: wave 2. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
27. US Renal Data System 2001 USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA